Listeria Monocytogenesstrain Strain Crs-207
Fallopian Tube Cancer
Explore 124 assets in Fallopian Tube Cancer →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Aduro Biotech, Inc.
Modality
vaccine
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02575807CT.gov Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Listeria Monocytogenesstrain Strain Crs-207 (this asset) | Aduro Biotech, Inc. | P1/2 | CCC · 48 |
| Mirvetuximab Soravtansine | AbbVie | P3 | BB |
| Adriamycin | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Carboplatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Irinotecan | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | GOG Foundation | P3 | BB |
| Nogitecan | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Epirubicin | OncoC4, Inc. | P3 | BB |
| Docetaxel | Genelux Corporation | P3 | BB |
+42 more in the Fallopian Tube Cancer cohort
Other indications for Listeria Monocytogenesstrain Strain Crs-207
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pancreatic Neoplasm | — | P2 | B · 61 |
| Pancreatic Adenocarcinoma | — | P2 | B · 57 |
| Pancreatic Neoplasm | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Listeria Monocytogenesstrain Strain Crs-207 in Fallopian Tube Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/listeria-monocytogenesstrain-strain-crs-207-fallopian-tube-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →